Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16442369 | 1.00 | SLC1A1 (0.53) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL6495348 | 1.00 | SLC1A1 (0.53) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL7494382 | 0.86 | SLC1A1 (0.55) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL800946 | 0.86 | SLC1A1 (0.55) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL3034357 | 0.86 | SLC1A1 (0.55) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL16743925 | 0.84 | ALDH1A1 (0.52) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL16743934 | 0.84 | ALDH1A1 (0.52) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL21246536 | 0.83 | ALDH1A1 (0.55) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL4909047 | 0.81 | KMT2A (0.49) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL4906646 | 0.81 | KMT2A (0.49) | SLC1A1CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | disclosed |
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | disclosed |
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | NOVO NORDISK A/S (DK) | 2014-01-09 | — | — | US | disclosed |
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | NOVO NORDISK A/S (DK) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | GLP1R, IAPP, GIPR | SLC1A1 1296/4885CA1 3060/4885CA2 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.